WuXi AppTec announced on 10 July a positive profit alert for the first half of 2025, with revenue reaching RMB 20.8 billion (USD 2.9 billion), up 20.6% year-on-year (YoY), while adjusted net profit surged 44.4% to RMB 6.3 billion. The growth was attributed to its integrated contract research, development and manufacturing organisation (CRDMO) model and operational efficiency improvements. Core business momentum remained strong, with non-GAAP net profit rising 44.4% excluding one-time gains from divesting shares in WuXi XDC.

The company's Hong Kong-listed shares jumped over 10% on 11 July, reflecting market confidence in its recovery after 2024's US Biosecure Act concerns. WuXi AppTec's oligonucleotides and peptides business grew 70.1% in 2024, while global capacity expansions, including Swiss and US facilities, are underway to support future growth.